Blood Cancer News and Research

RSS

Faulty gene function responsible for reducing survival times of leukaemia patients

Researchers have identified a genetic fault in some leukaemia patients that could be responsible for halving survival times after diagnosis compared to patients without the fault – an average reduction from 16 years to seven years. T

8 Dec 2015

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

Yale study identifies how myeloma cells escape treatment

One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse. A Yale Cancer Center study may have solved this mystery by identifying how cancer cells escape treatment, leading to recurrence.

7 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

30 Nov 2015

Scientists map out genes that keep cancer cells alive

Scientists have mapped out the genes that keep our cells alive, creating a long-awaited foothold for understanding how our genome works and which genes are crucial in disease like cancer.

26 Nov 2015

SkylineDx's MMprofiler receives CE-IVD certification

SkylineDx, today announced they have received CE-IVD registration from the European Competent Authority (Ministry of Health) for the MMprofiler, the company's prognostic test to determine the level of risk of a patient with multiple myeloma (MM).

25 Nov 2015

Leukemia & Lymphoma Society applauds FDA's recent approval of two new multiple myeloma drugs

The Leukemia & Lymphoma Society applauds the FDA's recent approval of two new drugs -- daratumumab and ixazomib -- to treat patients with relapsed multiple myeloma. These therapies are the latest in a growing arsenal to fight this blood cancer that impacts nearly 100,000 patients in the U.S. Advances in treatments for many different types of blood cancers are happening with dizzying speed and these two approvals in just one week are the latest evidence of this phenomenon.

23 Nov 2015

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.

21 Nov 2015

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.

17 Nov 2015

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous (SC) delivery of daratumumab with Halozyme's proprietary ENHANZE technology in multiple myeloma.

5 Nov 2015

Researchers discover key regulator that impacts survival of lymphoma patients

An important regulator that controls the ability of tumour cells to hide from the immune system in lymphoma patients, making them unlikely to respond to standard treatment, has been discovered by scientists at the University of Oxford.

31 Oct 2015

ESRD patients with multiple myeloma living longer than before, shows study

The risk of kidney failure caused by multiple myeloma appears to be declining, and survival is lengthening for patients who do develop kidney failure due to this cancer.

30 Oct 2015

Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

The New York Stem Cell Foundation announced today that Franziska Michor, PhD, is the 2015 recipient of the NYSCF - Robertson Stem Cell Prize for her work pioneering new approaches to study the growth, spread, and treatment of cancer. Her laboratory fuses her passions in mathematics, molecular biology and patient care to investigate how cancers form and progress.

29 Oct 2015

Researchers explain how incurable type of blood cancer develops

Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder. The findings could lead to more effective treatments and ways to identify those most at risk of developing the cancer.

18 Oct 2015

Antibiotic resistance potentially threatens the safety and efficacy of surgical procedures and immunosuppression therapies

This week The Lancet Infectious Diseases journal published the strongest evidence to date that increasing antibiotic resistance could have disastrous consequences for patients undergoing surgery or cancer chemotherapy. Based on a review of published literature, researchers predict that a 30% reduction in the efficacy of the prophylactic antibiotics routinely given when these procedures are performed could result in 120,000 more infections and 6300 infection-related deaths every year in the USA alone.

16 Oct 2015

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Preclinical experiments led by a team of researchers at VCU Massey Cancer Center have shown that blocking the production of a protein known as chromodomain helicase DNA-binding protein 4 (CHD4) may help increase the effectiveness of first-line treatments for acute myeloid leukemia (AML), a particularly lethal blood cancer that is increasing in incidence among older adults.

14 Oct 2015

Scientists create 3D image of key protein involved in blood and other cancer development

Scientists at the Walter and Eliza Hall Institute have created the first three-dimensional image of a key protein known to be involved in the development of blood and other cancers.

13 Oct 2015

UV robots help reduce rates of C. diff transmission among cancer inpatients

Robots are capable of all sorts of tasks to help better treat cancer: They connect oncologists to patients remotely, make incisions, staple them shut, deliver "nano" therapies--and they clean rooms. New research from Penn Medicine infection control specialists found that ultraviolet (UV) robots helped reduce the rates transmission of the common bacterial infection known as Clostridium difficile among cancer inpatients - mostly blood cancer patients, a group more vulnerable to hospital-acquired infections - by 25 percent. The interventions also saved about $150,000 in annual direct medical costs.

12 Oct 2015

Scientists engineer stem cells to better understand mechanisms behind leukemia

Scientists engineered stem cells to better understand the mechanisms behind a form of leukemia caused by changes in a key gene, according to a study led by Mount Sinai researchers and published online today in the journal Cell Reports.

9 Oct 2015

Blood Cancer News and Research

Faulty gene function responsible for reducing survival times of leukaemia patients

New approaches to treating leukemia, lymphoma and myeloma

Yale study identifies how myeloma cells escape treatment

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Scientists map out genes that keep cancer cells alive

SkylineDx's MMprofiler receives CE-IVD certification

Leukemia & Lymphoma Society applauds FDA's recent approval of two new multiple myeloma drugs

Ninlaro (ixazomib) approved to treat people with multiple myeloma

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

Researchers discover key regulator that impacts survival of lymphoma patients

ESRD patients with multiple myeloma living longer than before, shows study

Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

Researchers explain how incurable type of blood cancer develops

Antibiotic resistance potentially threatens the safety and efficacy of surgical procedures and immunosuppression therapies

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Scientists create 3D image of key protein involved in blood and other cancer development

UV robots help reduce rates of C. diff transmission among cancer inpatients

Scientists engineer stem cells to better understand mechanisms behind leukemia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News